Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Integrin alpha 2b beta 3

Integrin alpha 2b beta 3

Brief Information

Name:Integrin alpha-IIb/beta-3
Target Synonym:Platelet Glycoprotein GPIIb-IIIa Complex
Number of Launched Drugs:5
Number of Drugs in Clinical Trials:7
Lastest Research Phase:Approved

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
IT3-H52W8 Human Human Integrin alpha 2b beta 3 (ITGAIIb&ITGB3) Heterodimer Protein, His Tag&Tag Free
IT3-H52W8-structure
IT3-H52W8-sds
ACRO Quality

Part of Bioactivity data

IT3-H52W8-ELISA
 Integrin alpha 2b beta 3 ELISA

Immobilized Human Fibronectin at 2 μg/mL (100 μL/well) can bind Human ITGAIIb&ITGB3 Heterodimer Protein, His Tag&Tag Free (Cat. No. IT3-H52W8) with a linear range of 2-78 ng/mL (QC tested).

Synonym Name

Integrin alpha 2b beta 3,ITGAIIb&ITGB3

Background

Integrin alpha IIb beta 3 exist in a conformational equilibrium clustered around four main states. These conformations range from a compact bent nodule to two partially extended intermediate conformers and finally to a fully upright state. Activation of blood platelets by physiological stimuli at sites of vascular injury induces inside-out signaling, resulting in a conformational change of the prototype Integrin alpha IIb beta 3 from an inactive to an active state competent to bind soluble fibrinogen. Furthermore, ligand occupancy of Integrin alpha IIb beta 3 outside-in signaling and additional conformational changes of the receptor, leading to the exposure of extracellular neoepitopes termed ligand-induced binding sites (LIBS), which are recognized by anti-LIBS monoclonal antibodies.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Eptifibatide SB-1; C68-22; Sch-60936; CN-102702321 Approved Millennium Pharmaceuticals Inc Integrelin (former Brand Name), Integrilin EU Myocardial Infarction; Angina, Unstable Glaxosmithkline (Ireland) Ltd 1998-05-18 Myocardial Infarction; Angina, Unstable; ST Elevation Myocardial Infarction; Acute Coronary Syndrome; Anemia, Sickle Cell Details
Tirofiban Hydrochloride Hydrate L-462; MK-383; MK-0383; L-700462 Approved Merck Sharp & Dohme Corp 欣维宁, 艾卡特, Aggrastat United States Acute Coronary Syndrome; Thrombosis; Coronary Thrombosis Medicure Inc 1998-05-14 Renal Insufficiency; Angina, Unstable; Myocardial Infarction; Stroke; Acute Coronary Syndrome; Coronary Thrombosis; Thrombosis Details
Abciximab biosimilar (Reliance Life Sciences) R-TPR-019 Approved Reliance Life Sciences AbcixiRel India Angina, Unstable; Myocardial Ischemia Reliance Life Sciences 2013-01-01 Myocardial Ischemia; Angina, Unstable Details
Abciximab biosimilar (ISU Abxis) ISU-301 Approved Isu Abxis Co Ltd Clotinab, Faximab Myocardial Ischemia; Myocardial Infarction Details
Abciximab c7E3-Fab; c7E3-F(ab)2 Approved Eli Lilly And Company ReoPro United States Myocardial Ischemia Janssen Biotech Inc 1994-12-22 Myocardial Ischemia; Brain Ischemia; ST Elevation Myocardial Infarction; Myocardial Infarction; Arterial Occlusive Diseases; Angina, Unstable; Stroke; Acute Disease; Carotid Stenosis; Constriction, Pathologic; Renal Artery Obstruction Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
BGC-728 BGC-728 Phase 2 Clinical Btg Plc Myocardial Infarction; Stroke Details
EGT-022 EG-22; HU-005; EGT-022 Phase 2 Clinical Eyegene Inc Pressure Ulcer Details
HYC-11395 HYC-11395 Phase 1 Clinical Hefei Cosource Medicine Technology, Nanjing Heqi Pharmaceutical Technology Co Ltd Coronary Artery Disease; Thromboembolism Details
Pury Peptide MT-1001 Phase 1 Clinical Shaanxi Micot Technology Co Ltd Acute Coronary Syndrome Details
batifiban BAT-2094 Phase 3 Clinical Bio-Thera Solutions Ltd Myocardial Ischemia; Myocardial Infarction; Angina, Unstable; Angina Pectoris; Acute Coronary Syndrome; Thrombosis; Non-ST Elevated Myocardial Infarction Details
MT-1002(Shaanxi Micot Technology) MT-1002 Phase 2 Clinical Shaanxi Micot Technology Co Ltd Blood Coagulation Disorders; ST Elevation Myocardial Infarction; Angina, Unstable; Acute Coronary Syndrome; Stroke; Thrombocytopenia; Non-ST Elevated Myocardial Infarction; Thrombosis Details
Zalunfiban RUC-4 Phase 3 Clinical The Rockefeller University ST Elevation Myocardial Infarction Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message